>
Advanced Oncotherapy logo

AVO - Advanced Oncotherapy Share Price

34p 1.0  3.0%

Last Trade - 14/05/21

Sector
Healthcare
Size
Small Cap
Market Cap £115.3m
Enterprise Value £155.7m
Revenue £n/a
Position in Universe 1005th / 1827
Bullish
Bearish
Unlock AVO Revenue
Momentum
Relative Strength (%)
1m -15.9%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -34.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 49.8
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, AdvancedOncotherapy PLC revenues was not reported. Net lossincreased 8% to £12.2M. Higher net loss reflects FinanceCosts increase from £589K to £2.4M (expense). BasicEarnings per Share excluding Extraordinary Items increasedfrom -£0.07 to -£0.04.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for AVO
Graphical History

Revenue

AVO Revenue Unlock AVO Revenue

Net Income

AVO Net Income Unlock AVO Revenue

Normalised EPS

AVO Normalised EPS Unlock AVO Revenue

PE Ratio Range

AVO PE Ratio Range Unlock AVO Revenue

Dividend Yield Range

AVO Dividend Yield Range Unlock AVO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
AVO EPS Forecasts Unlock AVO Revenue
Profile Summary

Advanced Oncotherapy Plc is focused on providing radiotherapy systems for cancer treatment through the use of a proton therapy technology. The Company is engaged in development and then building of the Linac Image Guided Hadron Technology (LIGHT) proton beam cancer therapy device. The Company's segments include Development of Proton Therapy-UK; Development of Proton Therapy-Switzerland; Development of Proton Therapy-USA, and Healthcare-related properties-UK. Its LIGHT system integrates a series of modular linear accelerators. This feature offers hospitals and centers to customize treatment plans based on a range of energies. The Company's Research and development/ADAM S.A. (R&D/ADAM) facility is located on the campus of European Council for Nuclear Research (CERN), Geneva and Switzerland. The Company’s verification and validation site is located in Daresbury, United Kingdom.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated September 15, 2005
Public Since August 4, 2006
No. of Shareholders: n/a
No. of Employees: 129
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 349,409,021
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AVO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AVO
Upcoming Events for AVO
Monday 28th June, 2021 Estimate
Full Year 2020 Advanced Oncotherapy PLC Earnings Release
Thursday 29th July, 2021 Estimate
Advanced Oncotherapy PLC Annual Shareholders Meeting
Frequently Asked Questions for Advanced Oncotherapy
What is the Advanced Oncotherapy share price?

As of 14/05/21, shares in Advanced Oncotherapy are trading at 34p, giving the company a market capitalisation of £115.3m. This share price information is delayed by 15 minutes.

How has the Advanced Oncotherapy share price performed this year?

Shares in Advanced Oncotherapy are currently trading at 34p and the price has moved by 17.86% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Advanced Oncotherapy price has moved by -6.79% over the past year.

What are the analyst and broker recommendations for Advanced Oncotherapy?

Of the analysts with advisory recommendations for Advanced Oncotherapy, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Advanced Oncotherapy is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Advanced Oncotherapy next release its financial results?

Advanced Oncotherapy is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Advanced Oncotherapy dividend yield?

Advanced Oncotherapy does not currently pay a dividend.

Does Advanced Oncotherapy pay a dividend?

Advanced Oncotherapy does not currently pay a dividend.

When does Advanced Oncotherapy next pay dividends?

Advanced Oncotherapy does not currently pay a dividend.

How do I buy Advanced Oncotherapy shares?

To buy shares in Advanced Oncotherapy you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Advanced Oncotherapy?

Shares in Advanced Oncotherapy are currently trading at 34p, giving the company a market capitalisation of £115.3m.

Where are Advanced Oncotherapy shares listed? Where are Advanced Oncotherapy shares listed?

Here are the trading details for Advanced Oncotherapy:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: AVO
What kind of share is Advanced Oncotherapy?

Based on an overall assessment of its quality, value and momentum, Advanced Oncotherapy is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Advanced Oncotherapy share price forecast 2021?

Shares in Advanced Oncotherapy are currently priced at 34p. At that level they are trading at 0.256% discount to the analyst consensus target price of 34.09.

Analysts covering Advanced Oncotherapy currently have a consensus Earnings Per Share (EPS) forecast of -0.0787 for the next financial year.

How can I tell whether the Advanced Oncotherapy share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Advanced Oncotherapy. Over the past six months, the relative strength of its shares against the market has been -1.77%. At the current price of 34p, shares in Advanced Oncotherapy are trading at -7.68% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Advanced Oncotherapy PE Ratio?

We were not able to find PE ratio data for Advanced Oncotherapy.

Who are the key directors of Advanced Oncotherapy?

Advanced Oncotherapy's management team is headed by:

Michael Sinclair - CHM
Michael Bradfield - NED
Graham Pughe - SVP
Enrico Vanni - NED
Nicolas Serandour - CEO
Michel Baelen - OTH
Steve Myers - EDR
Hans von Celsing - NED
Nick Plowman - NED
Louise Harley-Smeur - SVP
Bridget Biggar - DHR
Ed Lee - COO
Ren Zhang - NED
Geraldine Poindron - SVF
Berengere Pons - Chabord - SVF
Who are the major shareholders of Advanced Oncotherapy?

Here are the top five shareholders of Advanced Oncotherapy based on the size of their shareholding:

Yantai CIPU Medical Technology Co Ltd Corporation
Percentage owned: 12.88% (45.0m shares)
Mulligan (Seamus) Individual Investor
Percentage owned: 8.7% (30.4m shares)
Celeste Management SA Corporation
Percentage owned: 8.11% (28.3m shares)
Glatz (Philippe) Individual Investor
Percentage owned: 4.48% (15.7m shares)
DNCA Invest - Beyond Global Leaders Mutual Fund
Percentage owned: 4.33% (15.1m shares)
Similar to AVO
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.